| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.04 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |